Pancreatic cancer suppressed by humanised anti-CKAP4 antibody
The humanised antibody, Hv1Lt1, showed promising results in pancreatic cancer mouse models.
List view / Grid view
The humanised antibody, Hv1Lt1, showed promising results in pancreatic cancer mouse models.
In this episode, we explore how mRNA technology could revolutionise cancer therapeutics.
Targeted alpha therapy shows promising preclinical results, increasing survival rate by 36.4 percent in recurrent tumours.
Researchers have developed a prediction model to ascertain breast cancer survivors’ risk of persistent taxane-induced peripheral neuropathy.
Researchers have discovered that pancreatic cancer’s resistance to chemotherapy is related to the physical stiffness of the extracellular matrix.
Researchers have developed a 3D approach to improve the characterisation of pancreatic intraepithelial neoplasias.
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
Dr Richard Cote and Dr Ramaswamy Govindan of the Washington University School of Medicine elucidate how AI, particularly deep learning networks, could identify histopathologic features in non-small cell lung cancer, and impact the treatment approach for early-stage patients.
A new proof-of-principle study demonstrates the DCAF5 protein is a promising target, which could avoid the need for toxic therapies.
The findings from DNA and RNA sequencing in primary and metastatic UTUC tumours could lead to strategies to improve patient outcomes.
A new study proves that organoid drug testing is highly accurate at predicting effective treatments and finds a novel therapeutic option.
Researchers suggest that DA histology slowly emerges by accumulating burdens of DNA damage and copy number aberrations.
Researchers discover that blocking PD-L2 in senescent cells increases the efficacy of chemotherapy in mouse models.
The ML algorithm explores how genetic mutations collectively influence a tumour’s reaction to drugs impeding DNA replication.
In this Q&A, Dr Lev Becker, Associate Professor, University of Chicago and Cofounder of Onchilles Pharma, reveals how his company is directing research into neutrophil biology to the advantage of cancer patients that need it most.